Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma

Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma

Background: This study investigated the impact of serum cytokeratin 19 fragment (CYFRA21-1) level on the clinical outcomes of patients with unresectable hepatocellular carcinoma (HCC) treated with sorafenib (SOR) or lenvatinib (LEN). Methods: A total of 71 cases with unresectable HCC taking SOR or L...

Full description

Bibliographic Details
Main Authors: Hitomi Takada, Leona Osawa, Yasuyuki Komiyama, Ryoh Kato, Natsuko Nakakuki, Masaru Muraoka, Yuichiro Suzuki, Akihisa Tatsumi, Mitsuaki Sato, Ei Takahashi, Shinichi Takano, Mitsuharu Fukasawa, Tatsuya Yamaguchi, Taisuke Inoue, Shinya Maekawa, Nobuyuki Enomoto
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Reports
Subjects:
CYFRA21-1
hepatocellular carcinoma
sorafenib
lenvatinib
Online Access:https://www.mdpi.com/2571-841X/4/3/25

Internet

https://www.mdpi.com/2571-841X/4/3/25

Similar Items